about
Recurrent SETBP1 mutations in atypical chronic myeloid leukemiaCEQer: a graphical tool for copy number and allelic imbalance detection from whole-exome sequencing data.Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseasesERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells.FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery.In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex.BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogeneERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents.Valproic acid enhances bosutinib cytotoxicity in colon cancer cells.The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition.Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.Recurrent ETNK1 mutations in atypical chronic myeloid leukemia.Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years.SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub.RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patientsColorectal Tumors Are Effectively Eradicated by Combined Inhibition of -Catenin, KRAS, and the Oncogenic Transcription Factor ITF2De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways
P50
Q27851991-FDD8A50B-494C-4FCD-8DCF-A1E55D9F419AQ30677391-AAD32CF5-0863-4945-8C37-2BA14D11DFBDQ30749239-79A94E7C-9FA4-43CF-AFB8-C73A1BFE7C3FQ34091302-A67EABBE-D21F-44D9-A23E-6B59324F2938Q34273644-1BD6E673-1C23-4211-AE18-E7B3B70027B3Q34582817-729AD752-FDFC-4B01-9A6B-43F31B4A1426Q36801093-6190A94A-FB4E-455E-9B06-CDFEAB766E5AQ38852493-B6BF4A56-F78C-48B8-9249-DF580F5C2A19Q38883101-9DC2807A-5EC5-461E-9478-C18942E890B5Q39898672-5483E444-4736-4A4D-AA04-C1EE344B0C2BQ42130801-82345ED4-1C07-491C-8C24-3D2A0D020E30Q42963571-98DB92F8-D1F2-44F5-A4EB-3E7DB00C5BEBQ44846247-3A4188BF-E915-44E5-8F3B-E880620AEE59Q54313514-41EE8B00-84BC-4A1B-A254-3803EF9651DBQ54479081-50E15D4B-7285-4860-8896-50594CE3D555Q54587549-AB492205-C218-48CB-963F-497FFE1721A1Q55045242-B910ED0C-714B-4B0F-BB66-171A820EF45EQ57748731-CDF2450D-980D-47BF-BBFA-43C8CF7C3919Q57748874-2D4E38A6-BCF1-4209-AA0F-54A1CBA57E7EQ92022489-08F7FD5C-7A05-4DDC-9F5E-B44C9F872DF9
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Vera Magistroni
@ast
Vera Magistroni
@en
Vera Magistroni
@es
Vera Magistroni
@nl
type
label
Vera Magistroni
@ast
Vera Magistroni
@en
Vera Magistroni
@es
Vera Magistroni
@nl
prefLabel
Vera Magistroni
@ast
Vera Magistroni
@en
Vera Magistroni
@es
Vera Magistroni
@nl
P106
P1153
15751232700
P31
P496
0000-0002-7334-9401